NAV per share rose 6.1% in Q2 and 1.8% for H1 2026, driven by strong MedCap and Stille performance, despite market volatility. Net profit reached SEK 258.1m in Q2 and SEK 81.2m for H1, with a solid equity ratio and active portfolio management.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.